Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | September 16, 2020 | News story | Research and Development | COVID, COVID-19 vaccine, coronavirus
The coronavirus news this week focuses on AstraZeneca’s vaccine candidate, as global trials for itsmuch-hyped vaccine were halted after an unexplained illness was identified in one of the participants but Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year.
In other news, England increased lockdown restrictions on Monday as coronavirus cases surged across the country.
1. Gatherings of over six people to be banned in England from Monday – Published on 09/09/20
England is set to increase lockdown restrictions across the country after a surge in coronavirus cases.
2. Chinese drug firm says thousands have been vaccinated for COVID-19 on an emergency use scheme – Published on 08/09/20
Hundreds of thousands of people in China have been inoculated with two experimental vaccines on an emergency use scheme, according to a state-owned vaccine developer.
3. AstraZeneca Chief Executive says vaccine is still possible this year – Published on 10/09/20
Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year, despite the clinical trials being paused after a participant became ill.
4. AstraZeneca slams brakes on COVID-19 vaccine trial over unexplained participant illness – Published on 09/09/20
Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted after an unexplained illness was identified in one of the participants.
5. Pfizer CEO says company’s COVID-19 vaccine will be available this year if FDA approves the candidate by October – Published on 14/09/20
Albert Bourla, the CEO of Pfizer, has said that the company’s vaccine for COVID-19 could be used by the general public before the end of the year if the FDA approves it by the end of October.
Conor Kavanagh
Related Content
Study links COVID-19 and some vaccines to increased risk of rare neurological condition
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection …
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …
Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines
French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive …
